Physician profile
Fallon Bauer
NPI 1114279049
$7,487.44
in general payments reported to CMS, 2019-2025
47 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $704 · 2023: $1,167 · 2024: $2,594 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,404 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,403.87 |
| Education | $123.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.10 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $575.11 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $399.27 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Harmony Biosciences LLC | $367.17 | 2023-2025 | Wakix |
| Biogen, INC. | $363.14 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $361.55 | 2021-2025 | |
| Emd Serono, INC. | $347.11 | 2023-2025 | Mavenclad |
| Ucb, INC. | $295.64 | 2023-2025 | Rystiggo, Briviact, Zilbrysq |
| Pfizer INC. | $281.06 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $273.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $252.63 | 2024-2025 | Crexont, Rytary |
| Lundbeck LLC | $235.74 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $229.89 | 2022-2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $152.87 | 2023-2025 | Hyqvia |
| Neurelis, INC. | $149.84 | 2024-2025 | Valtoco |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $144.63 | 2024-2025 | Sunosi |
| Argenx US, INC. | $115.64 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $114.57 | 2023-2025 | Rexulti |
| Watermark Medical, INC. | $112.52 | 2024 | |
| Jazz Pharmaceuticals INC. | $104.64 | 2024-2025 | |
| Janssen Biotech, INC. | $103.17 | 2025 | |
| Mallinckrodt Hospital Products INC. | $98.09 | 2024-2025 | Acthar |
| Genentech USA, INC. | $97.44 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $95.74 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $94.35 | 2021-2025 | Ingrezza |
| Ani Pharmaceuticals, INC. | $92.27 | 2025 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $88.41 | 2023-2025 | Radicava |
| Celgene Corporation | $84.54 | 2024-2025 | Zeposia |
| Sk Life Science, INC. | $72.02 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $65.48 | 2024-2025 | Lumryz |
| Acadia Pharmaceuticals INC | $60.89 | 2023-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $56.85 | 2024-2025 | Ultomiris |
| Kyowa Kirin, INC. | $49.93 | 2024-2025 | Nourianz |
| Allergan, INC. | $46.14 | 2021 | |
| Insightec,INC | $40.11 | 2025 | Exablate |
| Ge Healthcare | $30.77 | 2025 | |
| Horizon Therapeutics Plc | $29.24 | 2023 | Uplizna |
| Csl Behring | $28.31 | 2023 | Hizentra |
| Tactile Systems Technology INC | $24.79 | 2025 | Nimbl, Flexitouch Plus |
| Merz Pharmaceuticals, LLC | $23.12 | 2024 | Inbrija |
| Sumitomo Pharma America, INC. | $19.15 | 2023 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $19.06 | 2024 | |
| Cycle Pharmaceuticals INC | $18.90 | 2025 | Bafiertam, Tascenso Odt |
| Idorsia Pharmaceuticals US INC | $15.21 | 2023 | Quviviq |
| Life Molecular Imaging Ltd | $11.18 | 2024 | Neuraceq |
| Biohaven Pharmaceuticals, INC. | $11.16 | 2021 | |
| Sunovion Pharmaceuticals INC. | $10.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.